Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 1, 2003, Pages 7-17

  Waters, Norman C ^b   Geyer, Jeanne A ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NONE

Author keywords

Cell cycle; Cyclin dependent protein kinase (CDK); Drug development; Kinase inhibitors; Malaria; Pfmrk5; PfPK5; PfPK6; Plasmodium falciparum

Indexed keywords

AMINO ACID; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; CHLOROQUINE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYSTEINE PROTEINASE; FANSIDAR; FLAVONE DERIVATIVE; FLAVOPIRIDOL; HEMOGLOBIN; INDIRUBIN; KENPAULLONE; OLOMOUCINE; OXINDOLE; PURINE DERIVATIVE; PURVALANOL A; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROSCOVITINE;

ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GENE SEQUENCE; HUMAN; IN VITRO STUDY; MALARIA; MOLECULAR MODEL; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN DEGRADATION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIMALARIALS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MALARIA, FALCIPARUM; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTOZOAN PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037312866     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.1.7     Document Type: Review

References (66)

1. BREMAN JG: The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. (2001) 64(Suppl. 1-2):1-11.
2. TRAPE JF, PISON G, SPIEGEL A et al.: Combating malaria in Africa. Trends Parasitol. (2002) 18:224-230.
3. WINSTANLEY PA, WARD SA, SNOW RW. Clinical status and implications of antimalarial drug resistance. Microbes Infect. (2002) 4:157-164.
4. WONGSRICHANALAI C, PICKARD AL, WERNSDORFER WH et al.: Epidemiology of drug-resistant malaria. Lancet Infect. Dis. (2002) 2:209-218.
5. BLOLAND PB, LACKRITZ EM, KAZEMBE PN et al.: Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J. Infect. Dis. (1993) 167:932-937.
6. SHRETTA R, OMUMBO J, RAPUODA B et al.: Using evidence to change antimalarial drug policy in Kenya. Trop. Med. Int. Health (2000) 5:755-764.
7. SIBLEY CH, HYDE JE, SIMS PF et al.: Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. (2001) 17:582-588.
8. HYDE JE: Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. (2002) 4:165-174.
9. RIDLEY RG: Plasmodium: drug discovery and development - an industrial perspective. Exp. Parasitol. (1997) 87:293-304.
10. OLLIARO PL, YUTHAVONG Y: An overview of chemotherapeutic targets for antimalarial drug discovery. Pharmacol. Ther. (1999) 81:91-110.
11. DAMIENS E, MEIJER L: Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study. Pathol. Biol. (2000) 48:340-351.
12. GARRETT MD, WORKMAN P: Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer (1999) 35:2010-2030.
13. HAJDUCH M, HAVLIEEK L, VESELY J et al.: Synthetic cyclin-dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Exp. Med. Biol. (1999) 457:341-353.
14. MEIJER L, LECLERC S, LEOST M: Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. (1999) 82:279-284.
15. GRAY N, DETIVAUD L, DOERIG C et al.: ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. (1999) 6:859-875.
16. MORGAN DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann. Rev. Cell Dev. Biol. (1997) 13:261-291.
17. NURSE P: Ordering S phase and M phase in the cell cycle. Cell (1994) 79:547-550.
18. MORGAN DO: Principles of CDK regulation. Nature (1995) 374:131-134.
19. JEFFREY PD, RUSSO AA, POLYAK K et al.: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 376:313-320.
20. DE BONDT HL, ROSENBLATT J, JANCARIK J et al.: Crystal structure of cyclin-dependent kinase 2. Nature (1993) 363:595-602.
21. PAVLETICH NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. (1999) 287:821-828.
22. LEE MG, NURSE P: Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature (1987) 327(6117):31-35.
23. MEIJER L: Chemical inhibitors of cyclin-dependent kinases. Prog. Cell Cycle Res. (1995) 1:351-363.
24. FISCHER PM, LANE DP: Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. (2000) 7:1213-1245.
25. HARDCASTLE IR, GOLDING BT, GRIFFIN RJ: Designing inhibitors of cyclin-dependent kinases. Ann. Rev. Pharmacol. Toxicol. (2002) 42:325-348.
26. CARINI DJ, KALTENBACH RF, LIU J et al.: Identification of selective inhibitors of cyclin-dependent kinase 4. Bioorg. Med. Chem. Lett (2001) 11:2209-2211.
27. KIM KS, SACK JS, TOKARSKI JS et al.: Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem. (2000) 43:4126-4134.
28. ARNOT DE, GULL K: The Plasmodium cell-cycle: facts and questions. Ann. Trop. Med. Parasitol. (1998) 92:361-365.
29. LEETE TH, RUBIN H: Malaria and the cell cycle. Parasitol. Today (1996) 12:442-444.
30. DOERIG C, CHAKRABARTI D, KAPPES B et al.: The cell cycle in protozoan parasites. Prog. Cell Cycle Res. (2000) 4:163-183.
31. DOERIG C, HORROCKS P, COYLE J et al.: Pfcrk-1, a developmentally regulated cdc2-related protein kinase of Plasmodium falciparum. Mol. Biochem. Parasitol. (1995) 70:167-174.
32. ROSS-MACDONALD PB, GRAESER R, KAPPES B et al.: Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum. Eur. J. Biochem. (1994) 220:693-701.
33. GRAESER R, FRANKLIN RM, KAPPES B: Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol. Biochem. Parasitol. (1996) 79:125-127.
34. GRAESER R, WERNLI B, FRANKLIN RM et al.: Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles. Mol. Biochem. Parasitol. (1996) 82:37-49.
35. BRACCHI-RICARD V, BARIK S, DELVECCHI0 C et al.: PfPK6, a novel cyclin-dependent kinase/mitogen-activated protein kinase-related protein kinase from Plasmodium falciparum. Biochem. J. (2000) 347 Pt 1:255-263.
36. LE ROCH K, SESTIER C, DORIN D et al.: Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem. (2000) 275:8952-8958.
37. LI JL, ROBSON KJ, CHEN JL et al.: Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur. J. Biochem. (1996) 241:805-813.
38. WATERS NC, WOODARD CL, PRIGGE ST: Cyclin H activation and drug susceptibility of the Pfmrk cyclin-dependent protein kinase from Plasmodium falciparum. Mol. Biochem. Parasitol. (2000) 107:45-55.
39. SHUTTLEWORTH J: The regulation and functions of cdk7. Prog. Cell Cycle Res. (1995) 1:229-240.
40. SERIZAWA H, MAKELA TP, CONAWAY JW et al.: Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature (1995) 374:280-282.
41. KALDIS P. SUTTON A, SOLOMON MJ: The Cdk-activating kinase (CAK) from budding yeast. Cell (1996) 86:553-564.
42. KALDIS P, RUSSO AA, CHOU HS et al.: Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol. Biol. Cell (1998) 9:2545-2560.
43. CISMOWSKI MJ, LAFF GM, SOLOMON MJ et al.: KIN28 encodes a C-terminal domain kinase that controls mRNA transcription in Saccharomyces cerevisiae but lacks cyclin-dependent kinase-activating kinase (CAK) activity. Mol. Cell. Biol. (1995) 15:2983-2992.
44. LI Z, LE ROCH K, GEYER JA et al.: Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases. Biochem. Biophys. Res. Commun. (2001) 288:1207-1211.
45. BROWN NR, NOBLE ME, LAWRIE AM et al.: Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. (1999) 274:8746-8756.
46. RUSSO AA, JEFFREY PD, PAVLETICH NP: Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. (1996) 3:696-700.
47. HARMSE L, VAN ZYL R, GRAY N et al.: Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Biochem. Pharmacol. (2001) 62:341-348.
48. HONMA T, YOSHIZUMI T, HASHIMOTO N et al.: A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. (2001) 44:4628-4640.
49. VESELY J, HAVLICEK L, STRNAD M et al.: Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. (1994) 224:771-786.
50. SIELECKI TM, BOYLAN JF, BENFIELD PA et al.: Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. (2000) 43:1-18.
51. ARRIS CE, BOYLE FT, CALVERT AH et al.: Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. (2000) 43:2797-2804.
52. BARVIAN M, BOSCHELLI DH, COSSROW J et al.: Pyrido [2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. (2000) 43:4606-4616.
53. SONI R, MULLER L, FURET P et al.: Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. (2000) 275:877-884.
54. IKUTA M, KAMATA K, FUKASAWA K et al.: Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. (2001) 276:27548-27554.
55. BRAMSON HN, CORONA J, DAVIS ST et al.: Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. (2001) 44:4339-4358.
56. HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. (2001) 44:4615-4627.
57. NOBLE ME, ENDICOTT JA: Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther. (1999) 82:269-278.
58. SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (2000) 92:376-387.
59. DAVIS ST, BENSON BG, BRAMSON HN et al.: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science (2001) 291:134-137.
60. DE AZEVEDO WF, LECLERC S, MEIJER L et al.: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. (1997) 243:518-526.
61. XIAO Z, WATERS NC, WOODARD CL et al.: Design and synthesis of Pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett (2001) 11:2875-2878.
62. LI R, CHEN X, GONG B et al.: Structure-based design of parasitic protease inhibitors. Bioorg. Med. Chem. (1996) 4:1421-1427.
63. LI R, KENYON GL, COHEN FE et al.: In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem. (1995) 38:5031-5037.
64. LIU M, WILAIRAT P, GO ML: Antimalarial alkoxylated and hydroxylated chalcones: structure-activity relationship analysis. J. Med. Chem. (2001) 44:4443-4452.
65. DOMINGUEZ JN, CHARRIS JE, LOBO G et al.: Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur. J. Med. Chem. (2001) 36:555-560.
66. SUROLIA N, SUROLIA A: Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. (2001) 7:167-173.